AGP Executive Report

M&A in Oncology: Novartis agreed to acquire UK biotech Myricx Bio for $1.1B upfront plus up to $400M in milestones, aiming to strengthen its next-generation antibody-drug conjugate pipeline. FDA & Drug Access: The FDA’s June 2026 action roundup highlights ongoing acceptances, clearances, and alignments across neurology and other therapeutic areas, while Medicare’s new $50 GLP-1 coverage program expands access for eligible patients. Obesity Policy Shift: Medicare’s “Bridge” program (starting July 1) opens weight-management medication coverage for qualifying older adults, though it doesn’t cover the full range of long-term obesity care. Clinical Research Signals: A serum protein signature may help predict relapse risk in neuromyelitis optica spectrum disorder, and a gut-focused prebiotic study reports improved fermentation and liver-related metabolite profiles in overweight adults. Healthcare Operations: A practical guide targets the post-holiday surge in appointment demand, offering steps to protect schedules and staff. Public Health Watch: CDC is monitoring an expanding cyclosporiasis outbreak across 17 states with 145 cases. Care Workforce Risk: A Supreme Court move ending Haiti TPS could worsen caregiving shortages in U.S. healthcare settings.

Diagnostic Stewardship: An infectious-disease doctor argues the US overuses tests like urine cultures, driving unnecessary antibiotics and worsening resistance. Medication Safety: Pharmacist guidance flags B12 deficiency risks tied to meds such as proton pump inhibitors and metformin, while separate warnings cover side effects for omeprazole and metformin users. Healthcare Costs & Policy: Texas businesses feel squeezed as healthcare costs rise and lawmakers look for solutions; Ohio economists are split on Medicaid fraud-prevention reforms. Cancer Access: India’s cancer burden prompts a Rajya Sabha panel to seek ideas on affordable screening, diagnosis, and care. Regulatory & Industry Moves: CMS proposes “site-neutral” imaging payment reforms to cut $260M in spending; IDMA says nutraceuticals should stay OTC to support preventive care. Public Health Alerts: NYC reports 14 Legionnaires’ disease cases on the Upper East Side, with officials urging symptom monitoring. Care Delivery & Tech: AIIMS Delhi used blockchain-enabled tools to fill 460+ faculty vacancies; CommonSpirit Health apologizes for radiology report delays after outsourcing reads. Hospital Expansion: Fortis Healthcare signs an O&M deal for a 300-bed hospital in Odisha; Magnet Hospitals launches in Bengaluru with plans for 12 locations.

Regulatory Shift in Biotech: Hong Kong is moving toward a primary medical product evaluation model by 2030, aiming for faster access to innovative drugs and seeking WHO recognition for its CMPR to align with global standards. Cancer Risk Stratification: Clinicians highlighted how IPSS-M can uncover hidden high-risk biology in “lower-risk” myelodysplastic syndromes, helping guide earlier transplant decisions and treatment selection. Pulmonary Fibrosis Funding: Celea Therapeutics secured $180M for a pivotal head-to-head Phase 3 trial of deupirfenidone versus pirfenidone, targeting better tolerability and lung-function stabilization in idiopathic pulmonary fibrosis. HIV Treatment for Newborns: FDA accepted a priority-review sNDA for dolutegravir to extend use to newborns from birth, with EU validation also underway. Medical Sterilization Policy: EPA rescinded a costly ethylene oxide rule that threatened to shut down smaller sterilization facilities, easing pressure on the medical device supply chain. Public Health & Safety: A new report warns that texting an AI chatbot doesn’t reduce loneliness like real human contact does, while experts urge parents to limit screen use and push back on misinformation. Women’s Health: A gynaecologist cautioned against misuse of pregnancy prevention drugs, stressing side effects and the need for professional guidance.

NHS AI Rollout: England is accelerating a major AI push, including an NHS App AI triage tool to route patients to the right service and cut waiting lists, alongside AI notetaking to reduce admin. Public Health Data: The CDC reports the U.S. age-adjusted death rate hit a record low in 2025, driven in part by continued declines in overdose deaths even as influenza and pneumonia rose. Medical Innovation Policy: India’s National Medical Commission is urging medical colleges to use an ICMR-backed “Patent Mitra” initiative to patent and transfer healthcare innovations. Cell Therapy Capacity: India’s Jitendra Singh inaugurated a current good manufacturing practice facility for cellular therapy at ILBS, supporting advanced translational research and cell-based treatments. Healthcare Supply Chain Safety: Pakistan’s regulator set an Oct. 1 deadline for a barcode system to curb counterfeit medicines and plans to discontinue reusable syringes tied to HIV spread. Global Health Deal Scrutiny: Tanzania says it didn’t agree to US specimen sharing under a new health partnership, but key terms on data access and safeguards remain unclear. Clinical Research: A new review focuses on anemia and transfusion strategies for breast cancer patients receiving neoadjuvant chemotherapy, highlighting how practice varies and outcomes may differ.

Public Health Update: France discharged its first Ebola patient on French territory after two negative PCR tests, following a DRC-linked exposure on an Air France flight. Infectious Disease Watch: The CDC is investigating a growing cyclosporiasis outbreak, with at least 145 cases reported across 17 states and no deaths so far. Healthcare Access & Costs: Oklahoma approved a plan to fund ambulance services via a $5 monthly fee added to water bills, aiming to help residents with EMS costs after insurance. Cancer & Immunology: USC researchers report a scalable way to engineer macrophage progenitor cells, potentially boosting next-gen cancer-fighting cell therapies. Pharma & Tech: Pakistan plans a nationwide medicine barcode/QR verification system within 60 days to curb counterfeit and substandard drugs. Ophthalmology: A study suggests a fluorescence imaging “border zone” marker may predict how fast geographic atrophy lesions grow in age-related macular degeneration. Policy & Workforce: Nepal health officials say appointments at health sciences institutes will be transparent and competitive. Mental Health & Learning: A study links heavy reliance on AI for mental tasks with lower confidence and higher academic burnout/anxiety.

Pharma Supply Chain Security: Pakistan’s health ministry says it will roll out a nationwide medicine barcode and QR-code verification system within 60 days, aiming to help people confirm products are genuine and registered as counterfeit and substandard drugs remain a major risk. Oncology & Breast Surgery Tech: New cost and workflow analyses compare breast localization approaches (wire-guided needle vs MOLLI) and sentinel node dye options (methylene blue vs indocyanine green), focusing on delays, complications, and cost-effectiveness. Prostate Cancer Testing: A clinician review of IsoPSA performance reports how results may shift biopsy decisions, including in patients who did not have pre-biopsy mpMRI and those with low-to-intermediate mpMRI findings. Eye Care Innovation: A small UK case series finds an artificial corneal endothelial implant reduced corneal thickness and improved vision in chronic corneal oedema, including some patients after failed grafts. Multiple Sclerosis Progression Clue: Research links “foamy” fat-loaded immune cells in brain tissue to faster MS progression, suggesting a potential way to identify higher-risk patients. Healthcare Business Watch: India’s Manipal Hospitals is reportedly preparing a major IPO targeting about a $10B valuation. Public Health Alerts: The CDC reports tick-linked alpha-gal allergy markers in up to 31% of blood samples in some states, and the FDA upgraded a Utz potato chip recall to its highest risk category over possible salmonella contamination.

Food Safety: The FDA upgraded Utz potato chip recall to a Class I risk level over possible salmonella contamination in select Zapp’s and Dirty products, with “Best By” dates running Aug. 3–Aug. 31, 2026. Public Health: The CDC is investigating a spreading cyclospora parasite linked to watery diarrhea, with Michigan reporting a sharp rise and officials warning that contaminated produce and water are key routes. Medical Devices: Bioness won FDA 510(k) clearance for its PoNS system for dynamic gait deficit after chronic stroke, expanding use beyond its earlier MS indication as a home-use prescription adjunct to physical therapy. Healthcare Operations: CommonSpirit apologized after switching radiology providers, saying the change caused appointment delays and longer waits while it works to restore full services. Pharma & Policy: A new U.S. focus on pharma tariffs is raising uncertainty for branded drug imports, with companies scrambling ahead of a July 31, 2026 deadline. Infectious Disease Access: Merck reached an agreement with the ADAP Crisis Task Force to expand state HIV drug access to IDVYNSO for eligible patients. Cancer Care: Multiple myeloma coverage highlighted new approaches beyond BCMA, including GPRC5D-directed therapies and CELMoD mezigdomide.

Heat-Health Crisis: Belgium reported 39% more deaths than expected during a June heatwave, with France also seeing a nearly 30% jump—figures that are already pushing hospitals and emergency services and prompting new preparedness steps. Medicare Drug Costs: The Trump administration unveiled a Medicare rule aimed at cutting hospital markups on discounted medicines under the 340B program, projecting about $1.1B in first-year savings while hospital groups warn of funding pressure. CNS & Rare Disease Deals: Lonza secured Nona’s TfR1 blood-brain barrier tech to boost CNS delivery; Ipsen agreed to acquire Memo Therapeutics to advance a BK virus kidney-transplant therapy; AlzeCure signed a $2.2B+ licensing deal for its Alzheimer’s candidate ACD856. Cancer Screening & Precision Oncology: Zydus and Apollo Hospitals will bring Guardant’s Shield multi-cancer blood test to India for people 45+ at average risk. Clinical Research & Care Gaps: A study links long sedentary bouts to higher cancer death risk, while another review found many risk-prediction tools aren’t adopted widely enough in routine care. Stroke Rehab Standards: A new World Stroke Organization certification program targets consistent, higher-quality rehab access worldwide.

Cancer Care Tech: Color expands its “Expert Medical Opinion” with a peer-to-peer program that lets patients and oncologists connect with specialists for complex cases using claims and prior authorization data. Public Health Court Action: Pakistan’s Sindh High Court asks the provincial government for a report on alleged HIV transmission at a Karachi public hospital after families claim reused syringes led to child deaths. Digital Health & Safety: New research warns AI assistants can mirror human power biases, raising concerns for high-stakes roles like healthcare. FDA & Gene Therapy: FDA expands Vertex’s Casgevy (exa-cel) to children 2+ with sickle cell disease or transfusion-dependent beta-thalassemia. Medicare Drug Costs: CMS proposes limiting hospital markups on discounted 340B outpatient drugs, targeting about $1.1B in Medicare savings. Biotech Funding: PureTech spinout Celea Therapeutics raises $180M to advance its next IPF drug deupirfenidone into late-stage testing. MS Treatment Update: Sanofi’s tolebrutinib wins EU approval for disability progression in nonrelapsing secondary progressive multiple sclerosis.

Medical Tourism & Sustainability: Korea’s medical tourism leaders met to push a more sustainable, competitive model beyond treatment, building on record foreign patient arrivals and adding beauty and wellness as growth drivers. Dementia Prevention: A Lancet Healthy Longevity review says up to 45% of dementia cases link to modifiable risks, but awareness campaigns often fail to change behavior—calling for more personalized, community-led approaches. AI at Work: Administrative assistants and secretaries face AI-driven workload shifts, with some embracing tools to cut meeting prep time while broader job projections remain grim. Cybersecurity in Imaging: DHS’s CISA warned of vulnerabilities in a DICOM imaging toolkit (OFFIS DCMTK), raising risks of crashes and data exposure for healthcare workflows. Medicare GLP-1 Access: CMS launched a Medicare GLP-1 Bridge to expand access for eligible Part D beneficiaries through 2027. Home Health Policy: CMS proposed updates to 2027 home health payments, provider enrollment rules, and quality/value-based purchasing timelines. Breast Imaging Access: MIT researchers reported portable ultrasound tech that guides novice users for more consistent breast exams. PFAS in Medicines & Breast Milk: New findings highlight PFAS exposure concerns—from Dutch breast milk levels to research suggesting many PFAS-based medicines could be replaced with safer alternatives. Public Health Infrastructure: VCU opened a $30M liver and metabolic research imaging center to speed bench-to-bedside work using advanced PET/CT imaging.

Medicare Access: Novo Nordisk’s Wegovy “Medicare GLP-1 Bridge” starts July 1, offering eligible Medicare beneficiaries a $50 monthly copay through end of 2027, aiming to close a major coverage gap for obesity care. FDA Approvals: Viridian Therapeutics won FDA approval for Lumvoa (veligrotug) for thyroid eye disease with labeling covering both active and chronic disease; Moderna’s mRNA influenza vaccine candidate mRNA-1010 is moving toward an FDA decision after advisory support. New Treatments & Trial Signals: Abivax shares jumped after Phase 3 updates for obefazimod in ulcerative colitis eased cancer-risk worries; Sanofi’s avalglucosidase alfa met key endpoints in infantile-onset Pompe disease, supporting a label expansion push. Oncology & Rare Disease Deals: Ipsen plans to buy Memo Therapeutics in a potential ~$800M deal to expand rare disease pipeline, including a BK polyomavirus antibody. Healthcare Operations & Tech: UPS is investing $48M in temperature-controlled cross-dock facilities to speed cold-chain pharma logistics; NexusTek expands HIPAA-aligned managed IT and cybersecurity services for mid-market providers. Public Health & Care Delivery: A study links shingles vaccination to lower dementia risk; a UK trial found video-delivered cognitive rehab can produce sustained functional gains for long COVID cognitive symptoms.

AI & Exports: The U.S. lifted export controls that had blocked Anthropic’s Claude Fable 5 and partially restored Mythos 5 access, underscoring how national security rules can reshape health-tech and research availability. Regulatory & Safety: The FDA issued a Class 2 recall for some GE HealthCare image-processing servers after a software glitch could open the wrong patient’s exam, raising misdiagnosis risk. Pharma Oversight: A bipartisan U.S. House committee opened national security investigations into major drugmakers’ China clinical trial operations, focusing on data protection and oversight. FDA Manufacturing Pipeline: FDA selected seven companies for its PreCheck Pilot Program to speed regulatory engagement for new U.S. manufacturing sites. Cancer Care Advances: FDA approved a regulatory T-cell immunotherapy (Tregzi) with matched HSCT to improve chronic GVHD-free survival in hematologic malignancies. Public Health & Prevention: India’s organized screening push reported massive hypertension, diabetes, and cancer screening coverage, while experts urged HPV DNA-based cervical cancer screening over lower-accuracy approaches. Patient Voice in Imaging: Nearly all surveyed patients said they want to be told when AI is used in medical imaging, with many preferring written consent. Care Delivery: Roche will open a second Digital Tech Hub in Hyderabad to scale data-driven life sciences work.

HHS AI Push: HHS says it’s aligning across its AI strategy after a December 2025 RFI drew 7,300+ comments, with priorities on coordination, governance guidance, and better benchmarks for responsible clinical use. Cancer Care Updates: New education roundups spotlight 2026-era sequencing in CLL (BTK inhibitor vs time-limited venetoclax approaches), CAR T vs bispecifics in relapsed/refractory multiple myeloma, and EGFR-mutated NSCLC frontline debates (MARIPOSA vs FLAURA2), plus HER2+ metastatic breast cancer CNS screening and T-DXd/pertuzumab considerations. New Trial Signals: AbbVie reports fixed-duration epcoritamab+lenalidomide improved PFS in relapsed/refractory DLBCL versus R-GemOx, while topline data also highlight catadegbrutinib activity in Waldenström macroglobulinemia and real-world Medicare results favoring zanubrutinib over other BTK inhibitors in older adults. Healthcare Operations & Policy: Kaiser Permanente leaders argue innovation and financial sustainability can reinforce each other via clinician-led formulary reviews; meanwhile, revenue-cycle reporting warns of a “touch tax” from non-actionable claim follow-ups. Public Health Reminder: Cleveland Clinic urges parents to prevent hot-car tragedies, noting rapid temperature spikes and child vulnerability.

Drug Affordability & Policy: A new opinion piece argues U.S. families are getting squeezed by high prescription costs, with drug pricing tied to industry influence in Washington. Heat & Public Health: France is restricting alcohol sales and consumption in heatwave-hit areas, warning that drinking in extreme temperatures can rapidly raise dehydration, falls, and heat illness risk. Medication Safety: A toddler in India’s Madhya Pradesh allegedly lost eyesight after receiving the wrong eye/nasal medication, reigniting concerns about saline vs. non-sterile drops and medication error safeguards. Emergency Care Capacity: Wales’ emergency doctors warn “exit block” is driving avoidable deaths as EDs lack space to move patients out of corridors. Data Privacy: A Florida radiology group reports a data breach tied to unauthorized access to legacy systems, raising patient information concerns after acquisition. Diabetes Access: Australia’s PBS listing of Tresiba Penfill improves affordability for people with type 1 diabetes. AI in Healthcare: India’s Aarogya Setu 2.0 adds Google AI to digitize unstructured records into FHIR for interoperability. Cancer Pipeline: Interim results highlight Ac-225 rosopatamab tetraxetan activity in Lu-PSMA–pretreated metastatic prostate cancer. Healthcare Tech & Care Models: A new AI-native at-home testing partnership aims to close the gap between suspecting illness and getting follow-up care.

Workforce & Pay: MGMA data shows practice staff pay cooled in 2025, with many core roles still earning far more than five years ago—leaving limited budget relief for 2027. Acute Care Future: A new Future Healthcare Journal issue argues acute medicine is “more important than ever,” calling for continuous acute care supported by intelligent triage and portable diagnostics. Cancer Pipeline Updates: FDA accepted Replimune’s RP1 BLA resubmission for advanced melanoma; MARIPOSA panelists highlight amivantamab+lazertinib benefits (including CNS) with prophylaxis reducing serious toxicity; ASCO Breakthrough 2026 emphasized precision oncology, biomarkers, and AI. Biopharma Deals: Zymeworks agreed to buy Theravance Biopharma for about $929M, adding COPD drug Yupelri and royalty streams; Ipsen also moved on Kartos Therapeutics. Device Safety: Stryker recalled its InZone Detachment System over potential premature battery drain affecting neurovascular embolization. AI in Screening: UT Health San Antonio rolled out AI-assisted colonoscopy detection to flag hard-to-see precancerous polyps in real time. Policy & Access: Arizona job growth remains led by healthcare, while pharmacy middlemen reforms and PBM pass-through pricing debates continue to pressure drug costs.

Regulatory Pressure on Rare-Disease Drugs: EMA advisors say Amgen’s Tavneos (avacopan) should be pulled from sale after CHMP concerns that the ADVOCATE trial breached good clinical practice, with data found incorrect and misleading. Maternal Health Push: India’s Health Ministry will launch the SUMAN Roadmap 2030 to cut maternal and newborn deaths by 2030, using a life-cycle approach and high-risk pregnancy tracking across 130 districts and 13 priority states. AI in Cancer Manufacturing: A new AI-assisted production line for personalized cancer vaccines is rolling out, using rapid tumor DNA analysis to match treatments to patient mutations. Drug Supply Security: Ghana’s Pharmaceutical Society warns that 70% reliance on imported medicines threatens national security and urges investment to raise local manufacturing. Clinical Imaging Setback: FDA denied Lantheus’ application for a new PET imaging agent, citing issues at a third-party manufacturing site. Global Drug Use Record: UN reports 331 million people used drugs in 2024, with cocaine at record levels and a major treatment gap. Healthcare Innovation Ecosystems: New Jersey highlights its life sciences strength in a 2026 report, while Hong Kong launches IHIEA to speed cross-border healthcare innovation.